IRIX
IRIDEX Corporation1.0050
+0.0182+1.84%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
17.28MP/E (TTM)
-Basic EPS (TTM)
-0.30Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Iridex regains Nasdaq compliance
Iridex Corporation regained Nasdaq compliance on August 27, 2025, after satisfying the $2,500,000 stockholders' equity minimum under Listing Rule 5550(b)(1), based on its Q2 2025 10-Q filed August 12. This resolves the non-compliance flagged in May from Q1 results. Compliance secured. The closure stabilizes listing status amid ophthalmology market pressures.
8-K
IRIDEX Q2 revenue rises 7%
IRIDEX Corporation reported Q2 2025 revenue of $13.6 million, up 7% year-over-year, fueled by 10% growth in retina products to $8.0 million while Cyclo G6 stayed flat at $3.3 million. Operating expenses dropped 28% to $5.6 million, yielding a net loss of $1.0 million and positive adjusted EBITDA of $21 thousand—its third straight quarter. Cash dipped to $6.8 million. The firm targets cash flow breakeven and positive adjusted EBITDA for 2025, matching 2024 revenue levels. Progress builds momentum.
ALC
Alcon Inc.
79.02-0.17
ESMC
Escalon Medical Corp.
0.14+0.00
GKOS
Glaukos Corporation
113.76+2.03
IRMD
iRadimed Corporation
96.87-0.15
IRME
IR-Med Inc.
0.02-0.01
MASI
Masimo Corporation
134.52-2.88
QTRX
Quanterix Corporation
7.36-0.05
RTGN
RETINALGENIX TECHNOLOGIES INC
3.20+0.00
RXST
RxSight, Inc.
12.76+0.24
SGHT
Sight Sciences, Inc.
8.39+0.08